Spots Global Cancer Trial Database for primary peritoneal cancer
Every month we try and update this database with for primary peritoneal cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer | NCT01493505 | Fallopian Tube ... Ovarian Cancer Peritoneal Canc... | AMG 386 Paclitaxel AMG 386 Placebo Carboplatin | 18 Years - | Amgen | |
| Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer | NCT01166737 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | Tumor Debulking... | 18 Years - | AGO Study Group | |
| Determining Prognostic Immune Markers in Patients With Ovarian Cancer | NCT03862677 | Epithelial Ovar... | No intervention | 18 Years - | Leiden University Medical Center | |
| Trial of Pemetrexed and Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal Cancer | NCT00489359 | Ovarian Cancer Primary Periton... | Pemetrexed - Ph... Carboplatin - P... Pemetrexed - Ph... Carboplatin - P... | 18 Years - | Eli Lilly and Company | |
| Study of Safety & Biological Activity of IP IMNN-001 (Also Known as GEN-1) With Neoadjuvant Chemo in Ovarian Cancer | NCT02480374 | Epithelial Ovar... Fallopian Tube ... Primary Periton... | IMNN-001 | 18 Years - | Imunon | |
| Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients | NCT04227522 | Ovarian Cancer Fallopian Tube ... Primary Periton... Clear Cell Carc... | Rucaparib Placebos | 18 Years - | North Eastern German Society of Gynaecological Oncology | |
| Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer | NCT03704467 | Ovarian Cancer | M6620 Avelumab Carboplatin | 18 Years - | EMD Serono | |
| Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer | NCT02278783 | Ovarian Cancer Primary Periton... Fallopian Tube ... | regorafenib | 18 Years - | University of Utah | |
| Study of RO7515629 in Participants With HLA-G Positive Solid Tumors | NCT05769959 | Renal Cell Carc... Non-small Cell ... Pancreatic Aden... Colorectal Canc... Ovarian Neoplas... | RO7515629 tocilizumab | 18 Years - | Hoffmann-La Roche | |
| Study of Pemetrexed in the Treatment of Patients With Ovarian Cancer Who Have Failed Prior Platinum-Based Chemotherapy | NCT00109096 | Ovarian Neoplas... Primary Periton... | Pemetrexed | 18 Years - | Eli Lilly and Company | |
| Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer | NCT00063401 | Ovarian Cancer Peritoneal Neop... Fallopian Tube ... | Cetuximab: Paclitaxel Carboplatin | 18 Years - | Eli Lilly and Company | |
| Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors | NCT00520013 | Ovarian Cancer Fallopian Tube ... Primary Periton... Papillary Serou... Clear Cell Mull... | bevacizumab erlotinib paclitaxel carboplatin | 18 Years - | Dana-Farber Cancer Institute | |
| Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor | NCT05065021 | Ovarian Cancer Fallopian Tube ... Primary Periton... High Grade Sero... High Grade Endo... | Niraparib Dostarlimab Bevacizumab Paclitaxel | 18 Years - | University Health Network, Toronto | |
| TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer | NCT01493505 | Fallopian Tube ... Ovarian Cancer Peritoneal Canc... | AMG 386 Paclitaxel AMG 386 Placebo Carboplatin | 18 Years - | Amgen | |
| Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers | NCT02725489 | Breast Cancer Ovarian Cancer Fallopian Tube ... Primary Periton... Uterine Cancer Cervical Cancer Endometrial Can... | Vigil Durvalumab | 18 Years - | Mary Crowley Medical Research Center | |
| Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer | NCT00436215 | Ovarian Neoplas... Fallopian Tube ... Primary Periton... | Bevacizumab BAY 43-9006 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Single Arm Study of BSI-201 in Patients With BRCA-1 or BRCA-2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT00677079 | Primary Periton... Advanced Epithe... | Iniparib | 18 Years - | Sanofi | |
| A Trial to Find Out How Safe REGN5668 is and How Well it Works When Given With Either Cemiplimab or REGN4018 | NCT04590326 | Ovarian Cancer Fallopian Tube ... Primary Periton... Endometrial Can... | REGN5668 Cemiplimab REGN4018 Sarilumab | 18 Years - | Regeneron Pharmaceuticals | |
| Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer | NCT02483104 | Ovarian Cancer | veliparib carboplatin paclitaxel | 20 Years - 99 Years | AbbVie | |
| A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer | NCT03245892 | High Grade Sero... Fallopian Tube Primary Periton... | Carboplatin and... Nivolumab Cytoreductive s... Ipilimumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Panitumumab and Gemcitabine in Relapsed Ovarian Cancer | NCT01296035 | Ovarian Cancer Fallopian Tube ... Primary Periton... | Panitumumab | 18 Years - | Women and Infants Hospital of Rhode Island | |
| Flaxseed as Maintenance Therapy for Ovarian Cancer Patients in Remission | NCT02324439 | Epithelial Ovar... Fallopian Tube ... Primary Periton... | Omega Nutrition... | 21 Years - | Southern Illinois University | |
| A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027) | NCT01243762 | Neoplasms Malig... | dalotuzumab MK-0752 ridaforolimus MK-2206 | 18 Years - | Merck Sharp & Dohme LLC | |
| Efficacy and Safety of Pazopanib Monotherapy After First-line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Asian Women | NCT01227928 | Neoplasms, Ovar... | Pazopanib Placebo compara... | 18 Years - | GlaxoSmithKline | |
| RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer | NCT06173037 | Primary Periton... Fallopian Tube Epithelial Ovar... | RC88 | 18 Years - | RemeGen Co., Ltd. | |
| Phase II Study of Modified Triple Doublet Therapy in Women With Newly Diagnosed Mullerian Carcinoma | NCT00157560 | Ovarian Cancer Fallopian Tube ... Primary Periton... | Chemotherapy, m... | 18 Years - | Massachusetts General Hospital | |
| Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer | NCT02483104 | Ovarian Cancer | veliparib carboplatin paclitaxel | 20 Years - 99 Years | AbbVie | |
| A Study of SGN-B7H4V in Advanced Solid Tumors | NCT05194072 | Ovarian Neoplas... Peritoneal Neop... Fallopian Tube ... Triple Negative... HER2 Negative B... Hormone Recepto... Endometrial Neo... Carcinoma, Non-... Cholangiocarcin... Gallbladder Car... Adenoid Cystic ... | SGN-B7H4V | 18 Years - | Seagen Inc. | |
| Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma | NCT00226915 | Epithelial Ovar... Primary Periton... Fallopian Tube ... | Paclitaxel+Carb... Paclitaxel+Carb... | 20 Years - | Japanese Gynecologic Oncology Group | |
| Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian | NCT01219777 | Ovarian Cancer Primary Periton... Fallopian Tube ... | carboplatin Bevacizumab Paclitaxel | 18 Years - 90 Years | Ohio State University Comprehensive Cancer Center | |
| Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer | NCT02483104 | Ovarian Cancer | veliparib carboplatin paclitaxel | 20 Years - 99 Years | AbbVie | |
| Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer | NCT02606305 | Epithelial Ovar... Primary Periton... Fallopian Tube ... | Mirvetuximab so... Bevacizumab Carboplatin Pegylated Lipos... Pembrolizumab | 18 Years - | ImmunoGen, Inc. | |
| Flaxseed as Maintenance Therapy for Ovarian Cancer Patients in Remission | NCT02324439 | Epithelial Ovar... Fallopian Tube ... Primary Periton... | Omega Nutrition... | 21 Years - | Southern Illinois University | |
| Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer | NCT01220154 | Ovarian Cancer Fallopian Tube ... Primary Periton... No Prior Chemot... | Paclitaxel Carboplatin Bevacizumab | 18 Years - 90 Years | Ohio State University Comprehensive Cancer Center | |
| Study of Pemetrexed in the Treatment of Patients With Ovarian Cancer Who Have Failed Prior Platinum-Based Chemotherapy | NCT00109096 | Ovarian Neoplas... Primary Periton... | Pemetrexed | 18 Years - | Eli Lilly and Company | |
| Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT) | NCT05329545 | High Grade Sero... Fallopian Tube ... Primary Periton... | Upifitimab rils... Placebo | 18 Years - | Mersana Therapeutics | |
| A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma | NCT00082212 | Ovarian Cancer | Cetuximab | 18 Years - | Eli Lilly and Company | |
| Phase II Study of Clinical Activity of Pegaspargase in Women With Relapsed or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer | NCT01313078 | Ovarian Neoplas... Fallopian Tube ... Primary Periton... | Pegylated L-Asp... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer | NCT00928642 | Ovarian Cancer Primary Periton... | imatinib mesyla... Gemcitabine Int... | 18 Years - | Henry M. Jackson Foundation for the Advancement of Military Medicine | |
| A Beta-only IL-2 ImmunoTherapY Study | NCT05086692 | Advanced Solid ... Unresectable So... Clear Cell Rena... Triple Negative... Non-Small Cell ... Non-Small Cell ... Colorectal Canc... Gastric Cancer Cervical Cancer Basal Cell Carc... Bladder Cancer Merkel Cell Car... Squamous Cell C... Cutaneous Squam... Pleural Mesothe... Esophageal Canc... Endometrial Car... Solid Tumor Solid Tumor, Ad... MSI-H Solid Mal... Cancer With A H... Epithelial Ovar... Primary Periton... Gastroesophagea... Acral Melanoma Mucosal Melanom... Cutaneous Melan... DMMR Solid Mali... Fallopian Tube ... Ovarian Cancer MSI-H Cancer DMMR Cancer Pancreas Adenoc... Skin Cancer | MDNA11 Pembrolizumab | 18 Years - | Medicenna Therapeutics, Inc. | |
| TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer | NCT01204749 | Fallopian Tube ... Ovarian Cancer Primary Periton... | AMG 386 AMG 386 Placebo Paclitaxel Paclitaxel | 18 Years - | Amgen | |
| Panitumumab and Gemcitabine in Relapsed Ovarian Cancer | NCT01296035 | Ovarian Cancer Fallopian Tube ... Primary Periton... | Panitumumab | 18 Years - | Women and Infants Hospital of Rhode Island | |
| A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) | NCT01891344 | Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Peritoneal Canc... | Oral rucaparib | 18 Years - | pharmaand GmbH | |
| "Re-Stimulated" TILs And IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT01883297 | Recurrent Platinum-resist... High Grade Sero... Fallopian Tube ... Primary Periton... | Re-stimulated t... Interleukin-2 Cyclophosphamid... | 18 Years - | University Health Network, Toronto | |
| Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) | NCT05281471 | Platinum-resist... Platinum-refrac... Fallopian Tube ... Primary Periton... High-grade Sero... Endometrioid Ov... Ovarian Clear C... | olvimulogene na... Platinum chemot... Non-platinum ch... Bevacizumab (or... | 18 Years - | Genelux Corporation | |
| HIPEC After Initial CRS in Patients Who Have Received NACT | NCT03540017 | Ovarian Cancer Fallopian Tube ... Primary Periton... | Cisplatin | 18 Years - 85 Years | Northwell Health | |
| Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery | NCT02884648 | Malignant Neopl... Ovarian Cancer Fallopian Tube ... Primary Periton... | Bevacizumab | 18 Years - | M.D. Anderson Cancer Center | |
| Autologous OC-L Vaccine and Ovarian Cancer | NCT02452775 | Primary Ovarian... Fallopian Tube ... Primary Periton... | OC-L Montanide poly-ICLC (Hilt... | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Neoadjuvant Therapy for Ovarian Cancer | NCT01146795 | Epithelial Ovar... Primary Periton... Fallopian Tube ... | Carboplatin Paclitaxel Bevacizumab | 18 Years - | Columbia University | |
| Study of Paclitaxel in Patients With Ovarian Cancer | NCT00989131 | Epithelial Ovar... Primary Periton... Fallopian Tube ... | Paclical® Taxol® | 18 Years - | Oasmia Pharmaceutical AB | |
| A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | NCT03329950 | Melanoma Non-small Cell ... Breast Cancer Gastric Cancer Renal Cell Carc... Ovarian Cancer Cholangiocarcin... Bladder Urothel... Pancreatic Aden... Colorectal Canc... Esophageal Canc... Hepatic Cancer Head and Neck C... Primary Periton... Fallopian Tube ... Other Solid Tum... Diffuse Large B... Mantle Cell Lym... Indolent B-cell... Non-Hodgkin Lym... Follicular Lymp... Lymphoplasmacyt... Waldenstrom's D... Marginal Zone L... Mucosa Associat... Small Lymphocyt... | CDX-1140 CDX-301 pembrolizumab Chemotherapy | 18 Years - | Celldex Therapeutics | |
| Neoadjuvant Therapy for Ovarian Cancer | NCT01146795 | Epithelial Ovar... Primary Periton... Fallopian Tube ... | Carboplatin Paclitaxel Bevacizumab | 18 Years - | Columbia University | |
| Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients | NCT04227522 | Ovarian Cancer Fallopian Tube ... Primary Periton... Clear Cell Carc... | Rucaparib Placebos | 18 Years - | North Eastern German Society of Gynaecological Oncology | |
| First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer | NCT06063070 | Ovarian Cancer High Grade Sero... High Grade Endo... Primary Periton... Fallopian-tube ... | Fluzoparib Caps... Bevacizumab | 18 Years - | Sun Yat-sen University | |
| Factors Associated With the Use of a High Volume Cancer Center by Black Women With Ovarian Cancer: A Qualitative Study | NCT02928549 | Ovarian Cancer Fallopian Tube ... Primary Periton... | semi-structured... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Prospective Trial of COXEN Chemotherapy Prediction | NCT01228942 | Ovarian Neoplas... Fallopian Tube ... | COXEN analysis ... | 18 Years - 95 Years | University of Virginia | |
| Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT00616941 | Epithelial Ovar... Fallopian Tube ... Primary Periton... | NY-ESO-1 OLP4 NY-ESO-1 OLP4 +... NY-ESO-1 OLP4 +... | 18 Years - | Ludwig Institute for Cancer Research | |
| Gleevec Study for Patients With Ovarian Cancer | NCT00510653 | Ovarian Cancer | Imatinib Mesyla... | 18 Years - | M.D. Anderson Cancer Center | |
| Hu3S193 in Treating Women With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | NCT00617773 | Fallopian Tube ... Ovarian Cancer Primary Periton... | hu3S193 | 18 Years - | Recepta Biopharma | |
| PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer | NCT01899599 | Ovarian Epithel... Fallopian Tube ... Primary Periton... | PankoMab-GEX Placebo | 18 Years - | Glycotope GmbH | |
| Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers | NCT01237067 | Ovarian Cancer Breast Cancer Primary Periton... Fallopian Tube ... Endometrial Can... | Carboplatin Olaparib | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer | NCT02948426 | Fallopian Tube ... Ovarian Cancer Primary Periton... | Autologous Mono... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Niraparib as Maintenance Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer | NCT04546373 | Epithelial Ovar... Fallopian Tube ... Primary Periton... | Niraparib | 18 Years - | Grupo Español de Investigación en Cáncer de Ovario | |
| Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype | NCT05574673 | Ovarian Cancer Primary Periton... Fallopian Tube ... | Standard of car... | 18 Years - 100 Years | Nordic Society of Gynaecological Oncology - Clinical Trials Unit | |
| Efficacy and Safety of Pazopanib Monotherapy After First-line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Asian Women | NCT01227928 | Neoplasms, Ovar... | Pazopanib Placebo compara... | 18 Years - | GlaxoSmithKline | |
| Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer | NCT00063401 | Ovarian Cancer Peritoneal Neop... Fallopian Tube ... | Cetuximab: Paclitaxel Carboplatin | 18 Years - | Eli Lilly and Company | |
| Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer | NCT01196741 | Ovarian Cancer Fallopian Tube ... Primary Periton... | Paclitaxel Saracatinib Matched placebo | 18 Years - | University College, London | |
| Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer | NCT05494580 | Ovarian Cancer Ovarian Carcino... Platinum-resist... Fallopian Tube ... Primary Periton... | Pamiparib Surufatinib | 18 Years - 75 Years | Sun Yat-sen University | |
| Collection of Malignant Ascites, Pleural Fluid, and Blood From People With Solid Tumors | NCT03189108 | Ovarian Cancer Primary Periton... Fallopian Tube ... Cancer | 18 Years - | National Institutes of Health Clinical Center (CC) | ||
| Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers | NCT01237067 | Ovarian Cancer Breast Cancer Primary Periton... Fallopian Tube ... Endometrial Can... | Carboplatin Olaparib | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Safety Study of a Genetically Modified Adenovirus in Ovarian Cancer Patients | NCT00562003 | Ovarian Cancer Primary Periton... | Tenckhoff Cathe... Ad5-delta24RGD | 19 Years - | University of Alabama at Birmingham | |
| Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study | NCT04539327 | Epithelial Ovar... Fallopian Tube ... Primary Periton... | Rucaparib | 18 Years - | Grupo Español de Investigación en Cáncer de Ovario | |
| Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer | NCT05739981 | Ovarian Cancer Fallopian Tube ... Primary Periton... | Paclitaxel Carboplatin Bevacizumab IMNN-001 | 18 Years - | Imunon | |
| Autologous OC-L Vaccine and Ovarian Cancer | NCT02452775 | Primary Ovarian... Fallopian Tube ... Primary Periton... | OC-L Montanide poly-ICLC (Hilt... | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations | NCT01989546 | Advanced Ovaria... Primary Periton... Advanced Breast... Advanced Solid ... | BMN 673 | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT03635489 | Ovarian Cancer Fallopian Tube ... Primary Periton... | Paclitaxel Bevacizumab Carboplatin Placebo | 18 Years - | Hoffmann-La Roche | |
| Trial of Pemetrexed and Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal Cancer | NCT00489359 | Ovarian Cancer Primary Periton... | Pemetrexed - Ph... Carboplatin - P... Pemetrexed - Ph... Carboplatin - P... | 18 Years - | Eli Lilly and Company | |
| Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers | NCT01237067 | Ovarian Cancer Breast Cancer Primary Periton... Fallopian Tube ... Endometrial Can... | Carboplatin Olaparib | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations | NCT01989546 | Advanced Ovaria... Primary Periton... Advanced Breast... Advanced Solid ... | BMN 673 | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| A Clinical Study of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer | NCT04029909 | Ovarian Epithel... Fallopian Tube ... Primary Periton... | Gimatecan 0.6mg... 0.8mg/m2/d 0.4mg/m2/d | 18 Years - 65 Years | Lee's Pharmaceutical Limited |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
